All In Biotech

NDA 205525 · Wellhouse Pharma

Syndros

Dronabinol · Oral · Cannabinoid

Discontinued

Last checked: Nov 20, 2026Latest source record: May 17, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Jul 1, 2016

Approved uses

1

Original approval plus efficacy supplements

Registered trials

354

68 Phase 3, 52 recruiting

FAERS reports

5,133

3,836 serious, 1,169 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 21, 2026.

SYNDROS is indicated in adults for the treatment of: anorexia associated with weight loss in patients with Acquired Immune Deficiency Syndrome (AIDS). nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. SYNDROS is a cannabinoid indicated in adults for the treatment of: anorexia associated with weight loss in patients with AIDS. ( 1 ) nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. ( 1 )

Mechanism: Dronabinol is an orally active cannabinoid that has complex effects on the CNS, including central sympathomimetic activity. Cannabinoid receptors have been discovered in neural tissues. These receptors may play a role in mediating the effects of dronabinol.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • SYNDROS · DRONABINOL 5MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SOLUTION, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Dronabinol" as an intervention, any sponsor and status, largest first.

All 354 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea485
  • fatigue420
  • off label use388
  • diarrhoea387
  • death383
  • toxicity to various agents341
  • drug abuse309
  • vomiting281
  • decreased appetite275
  • pain253
  • weight decreased237
  • drug screen positive225

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200412
200516
200622
200716
200816
200927
201036
201158
201260
201380
2014136
2015211
2016246
2017338
2018477
2019512
2020439
2021407
2022415
2023465
2024495
2025397
2026252

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 147 on PubMed

Sponsor: Wellhouse Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.